These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 10363966)
21. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994 [TBL] [Abstract][Full Text] [Related]
22. HER2 regulatory control of angiopoietin-2 in breast cancer. Carter WB; Ward MD Surgery; 2000 Aug; 128(2):153-8. PubMed ID: 10922985 [TBL] [Abstract][Full Text] [Related]
23. Oncogenic activation of the human Pygopus2 promoter by E74-like factor-1. Andrews PG; Kennedy MW; Popadiuk CM; Kao KR Mol Cancer Res; 2008 Feb; 6(2):259-66. PubMed ID: 18314487 [TBL] [Abstract][Full Text] [Related]
24. A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir. Maeda T; O-Wang J; Matsubara H; Asano T; Ochiai T; Sakiyama S; Tagawa M Cancer Gene Ther; 2001 Nov; 8(11):890-6. PubMed ID: 11773979 [TBL] [Abstract][Full Text] [Related]
25. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer. Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499 [TBL] [Abstract][Full Text] [Related]
26. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Fox SB; Bragança J; Turley H; Campo L; Han C; Gatter KC; Bhattacharya S; Harris AL Cancer Res; 2004 Sep; 64(17):6075-81. PubMed ID: 15342390 [TBL] [Abstract][Full Text] [Related]
27. Hormonal regulation of the c-fms proto-oncogene in breast cancer cells is mediated by a composite glucocorticoid response element. Flick MB; Sapi E; Kacinski BM J Cell Biochem; 2002; 85(1):10-23. PubMed ID: 11891846 [TBL] [Abstract][Full Text] [Related]
28. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Han S; Inoue H; Flowers LC; Sidell N Clin Cancer Res; 2003 Oct; 9(12):4627-35. PubMed ID: 14555539 [TBL] [Abstract][Full Text] [Related]
29. Identification of a minimal c-erbB-2 promoter region that mediates preferential expression of a linked foreign gene in human breast cancer cells. Yu L; Kamo S; Tagawa M Int J Oncol; 2002 Mar; 20(3):607-10. PubMed ID: 11836576 [TBL] [Abstract][Full Text] [Related]
30. Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma. Tanaka S; Mori M; Akiyoshi T; Tanaka Y; Mafune K; Wands JR; Sugimachi K Cancer Res; 1997 Jan; 57(1):28-31. PubMed ID: 8988034 [TBL] [Abstract][Full Text] [Related]
31. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Bosher JM; Totty NF; Hsuan JJ; Williams T; Hurst HC Oncogene; 1996 Oct; 13(8):1701-7. PubMed ID: 8895516 [TBL] [Abstract][Full Text] [Related]
32. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. Delacroix L; Begon D; Chatel G; Jackers P; Winkler R DNA Cell Biol; 2005 Sep; 24(9):582-94. PubMed ID: 16153159 [TBL] [Abstract][Full Text] [Related]
33. Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide. Porumb H; Gousset H; Letellier R; Salle V; Briane D; Vassy J; Amor-Gueret M; Israël L; Taillandier E Cancer Res; 1996 Feb; 56(3):515-22. PubMed ID: 8564964 [TBL] [Abstract][Full Text] [Related]
34. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Bosher JM; Williams T; Hurst HC Proc Natl Acad Sci U S A; 1995 Jan; 92(3):744-7. PubMed ID: 7846046 [TBL] [Abstract][Full Text] [Related]
35. HER2 fragmentation and breast cancer stratification. Arribas J; Parra-Palau JL; Pedersen K Clin Cancer Res; 2010 Aug; 16(16):4071-3. PubMed ID: 20682714 [TBL] [Abstract][Full Text] [Related]
36. Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. Miller SJ; Xing X; Xi L; Hung MC DNA Cell Biol; 1996 Sep; 15(9):749-57. PubMed ID: 8836033 [TBL] [Abstract][Full Text] [Related]
37. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. Hollywood DP; Hurst HC EMBO J; 1993 Jun; 12(6):2369-75. PubMed ID: 8099545 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides. Noonberg SB; Scott GK; Hunt CA; Hogan ME; Benz CC Gene; 1994 Nov; 149(1):123-6. PubMed ID: 7958975 [TBL] [Abstract][Full Text] [Related]
39. Capture and identification of proteins that bind to a GGA-rich sequence from the ERBB2 gene promoter region. Zhang T; Zhang H; Wang Y; McGown LB Anal Bioanal Chem; 2012 Oct; 404(6-7):1867-76. PubMed ID: 22899247 [TBL] [Abstract][Full Text] [Related]
40. Post-transcriptional control of c-erb B-2 overexpression in stomach cancer cells. Bae CD; Juhnn YS; Park JB Exp Mol Med; 2001 Mar; 33(1):15-9. PubMed ID: 11322480 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]